Literature DB >> 4161770

Testosterone potentiated 32P therapy in prostatic carcinoma.

R M Donati, H Ellis, N I Gallagher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1966        PMID： 4161770     DOI： 10.1002/1097-0142(196608)19:8<1088::aid-cncr2820190806>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  4 in total

1.  Androgen therapy in advanced carcinoma of the prostate.

Authors:  A Morales; J G Connolly; A W Bruce
Journal:  Can Med Assoc J       Date:  1971-07-10       Impact factor: 8.262

2.  The use of radioactive phosphorus to treat bone pain in metastatic carcinoma of the prostate.

Authors:  A Morales; R C Burr; A W Bruce
Journal:  Can Med Assoc J       Date:  1970-08-15       Impact factor: 8.262

3.  Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer.

Authors:  A J Suarez; D L Lamm; H M Radwin; M Sarosdy; G Clark; C K Osborne
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Strontium 89 for palliation of bone metastases.

Authors:  E K Reddy; R G Robinson; C M Mansfield
Journal:  J Natl Med Assoc       Date:  1986-01       Impact factor: 1.798
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.